On June 6, 2023 Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Aixindawei" or "the Company") reported that the company’s independently developed broad-spectrum targeted small molecule anti-cancer new drug AST-3424 has achieved the preset goals of the first phase of the Phase II clinical trial ahead of schedule and officially entered the second phase (Press release, Ascentawits Pharmaceuticals, JUN 6, 2023, View Source [SID1234650305]). This is another important milestone for Aixindawei after completing the Phase I clinical study of AST-3424 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Duan Jianxin, Chairman of Aixindawei, said: "After central imaging evaluation, the first stage of Phase II reached the preset goal ahead of schedule and entered the second stage. There are obvious clinical benefits for patients with specific gene mutations. We hope that AST-3424 can become the first precise targeted drug for liver cancer and bring hope to liver cancer patients around the world."

About AST-3424

AST-3424 is an innovative small molecule conjugate drug. After entering tumor cells overexpressing the AKR1C3 enzyme, it can be highly selectively activated by the AKR1C3 enzyme to release effective drugs and achieve precise killing of tumor cells. In the Phase I clinical study of solid tumors, AST-3424 showed good safety and tolerability. With the further development of subsequent clinical trials, the company will combine the companion diagnostic kit developed independently to achieve precise treatment of patients with different AKR1C3 expression levels.